Summary: With advances in antiretroviral therapy, many HIV＋ individuals are living longer lives and some are developing end-stage renal and W or hepatic disease requiring transplantation. These patients require concomitant use of immunosuppressants (e.g., cyclosporine [CsA]) and antiretrovirals (e.g., protease inhibitors [PIs]), which exhibit narrow therapeutic windows and are substrates and inhibitors of cytochrome P450 3A enzymes and the cellular transporter P-glycoprotein. In this pilot study, HIV＋ subjects on either oral nelˆnavir (NFV) or indinavir (IND) with nondetectable viral loads and normal renal and hepatic function had 12 hour pharmacokinetic (PK) studies on 3 separate days: PIs alone, PIs＋ intravenous CsA, and PIs＋oral CsA to determine the extent of PK interactions between these medications. PIs and CsA concentrations were measured by LC W MS in plasma and whole blood, respectively. Nine subjects (n＝7 on NFV, n＝2 on IND) completed the study. Only the results of those subjects taking NFV are reported. Oral co-administration of CsA increased NFV T max from 2.6±0.9 to 3.2±0.8 h (pº0.05), and AUC 0-/ from 27.9±15.2 to 43.2±27.1 mg * h W mL (p＝0.06). Intravenous CsA did not appreciably alter oral pharmacokinetics of NFV. Both CsA and NFV PK parameters exhibited a high degree of intersubject variability, underscoring the need for routine therapeutic drug monitoring of both CsA and PIs in HIV＋ subjects undergoing transplantation.
Introduction
Traditionally, patients with HIV disease have been excluded from consideration for transplantation because of concerns about the safety of further immunosuppression from transplant medications as well as reluctance to allocate scarce resources to those with a poor prognosis. With the tremendous advances in antiretroviral therapy in the last few years, patients are now living much longer, and dying from concomitant renal and liver disease rather than HIV disease. The University of California San Francisco (UCSF) has recently begun a protocol for solid organ transplantation in HIV＋ patients.
Protease inhibitors such as nelˆnavir and indinavir, which are commonly used by patients with HIV to decrease viral replication, are substrates and inhibitors of the cytochrome P450 metabolizing enzyme CYP3A4.
Cyclosporine, an immunosuppressant used to prevent transplant rejection, is a CYP3A4 substrate as well as an inhibitor. In addition, both cyclosporine and protease inhibitors are substrates and inhibitors of Pglycoprotein, a transporter found on the apical membranes of intestinal and hepatic epithelial cells, whose function is to increase the excretion of its substrates. In intestinal cells, P-glycoprotein and CYP3A4 act as à`g auntlet'', either pumping the drug back out of the cell, or metabolizing it before it is absorbed. 1) Therefore, concomitant administration of inhibitors of both P-glycoprotein and CYP3A4 systems would be expected to increase both cyclosporine and protease inhibitors bioavailability.
However, the extent of their potential drug interactions is unknown. Since both types of medications have narrow therapeutic windows, the ability to predict the degree of interaction would help clinicians correctly In this pilot study, we examine the degree of interaction between these agents.
Methods
Study design and subjects: The study was an openlabel, single dose trial comparing the pharmacokinetics of an oral dose of protease inhibitor alone and with one dose of intravenous and one oral cyclosporine (Neoral } ) dose, administered on consecutive days. Nine HIV＋ subjects, eight men and one woman, mean age 41±5 years, mean weight 81±16 kg on protease inhibitors for at least 3 months with undetectable viral loads were recruited for this study ( Table 1) . Eight were Caucasian and one was of Hispanic origin. All subjects were nonsmokers, had normal renal and hepatic function, and had no intercurrent illnesses when studied. The female subject also had a negative pregnancy test. At the end of the 3-day study, subjects had repeat safety labs drawn and a repeat physical examination and were discharged. This study was approved by the UCSF IRB, and all study subjects gave signed informed consent.
Study procedures: Subjects were admitted to the UCSF General Clinical Research Center for a 3-day stay. The study started at 7 am on Day 1 after an overnight fast. An indwelling catheter was inserted into a forearm vein. After drawing baseline safety and trough blood samples, at 8 am, subjects took their protease inhibitor(s). Blood was sampled from the indwelling catheter at diŠerent time intervals, depending on which protease inhibitor subjects were taking: for indinavir dosed every 8 hours, blood was sampled at times 0, 30, 45, 60, 90, 120, 150, 180, 240, 360 and 480 minutes; for all other protease inhibitors dosed on an every 12 hour schedule, blood was sampled at 0, 30, 60, 120, 150, 180, 210, 240, 300, 360 and 480 and 720 minutes. No food was allowed for theˆrst three hours after the study was started, and all subjects ate the same meal every day at the same times relative to taking their medication.
CaŠeine intake was limited to º300 mg W day. No grapefruit or grapefruit juice was allowed.
On Day 2, subjects had a second indwelling catheter inserted into the other arm, and at 8 am, the subjects took their protease inhibitors and a continuous infusion of cyclosporine (Neoral } ) 2.0 mg W kg was given over 150 minutes. Blood samples were drawn as on Day 1. On Day 3, at 8 am subjects took their protease inhibitors and an oral dose of cyclosporine (Neoral } ) 4.0 mg W kg simultaneously. Blood samples were drawn as on Day 1.
Analysis of blood samples: Blood samples were spun down and frozen at -709 C until analyzed. Serum was analyzed for nelˆnavir, indinavir, saquinavir and ritonavir, and whole blood was analyzed for cyclosporine.
Brie‰y, to 0.1 mL plasma was added 0.5 mL methanol W 0.2 M ZnSO4 (7 W 3 v W v) containing 0.8 mg W mL internal standard pepstatin, for protein precipitation. Five mL of the supernatant were directly injected into the HPLC W MS system and onto a 20×4 mm extraction columnˆlled with Hypersil MOS, 5 mm particle size (Shandon, Chadwick, UK). Samples were washed with 10z methanol and 90z 2 mM ammonium acetate. The ‰ow rate was 5 mL W min. After 1.0 min, the column switching valve was activated and the analytes were eluted in back‰ush mode from the extraction column onto the 30×2.1 mm XDB-C8, 3.5 mM analytical column (Eclipse, Hewlett-Packard, Palo Alto, CA).
The mobile phase consisted of methanol and 2 mM ammonium acetate. The following gradient was run: Run time 0¿1 min: 50z methanol; 1¿5 min: 50¿86z methanol; 5.5 min: 95z methanol. The ‰ow rate was 0.5 mL W min and the column was kept at 409 C. The total run time was 7.95 min. Single ions were recorded. Since under the conditions used, the sodium adducts [M＋ Na]
＋ give the strongest signals, the mass spectrometer was focused on m W z＝687 (pepstatin), the internal standard, m W z＝721 (ritonavir), m W z＝568 (nelˆnavir), m W z ＝672 (saquinavir) and m W z＝615 (indinavir) with a dwell time of 195 ms. The assay was validated following current FDA guidelines. 2) Whole blood samples were analyzed for cyclosporine by a validated HPLC W MS assay in combination with automated online sample preparation (LC W LC-MS, Hewlett-Packard; Palo Alto, CA). Brie‰y, 0.5 mL of a blood sample was transferred into an Eppendorf tube. One mL methanol W ZnSO4 (80 W 20 v W v) protein precipitation reagent containing 50 mg W L of the internal standard ascomycin (Sigma Chemicals, St. Louis, MO) was then added. Samples were vortex mixed and centrifuged. The supernatant was transferred into an HPLC vial and 100 mL were injected onto a 10.2 mm reverse phase extraction column (HPLC I: G1311A quarternary pump, G1322A degasser and G1329A autosampler equipped with a G1330A thermostat). The sample was concentrated and washed with methanol W 0.1z formic acid (40 W 60 v W v, ‰ow 6 mL W min) for 0.7 min. Hereafter, the column-switching valve connecting HPLC I (samples extraction) and HPLC II (separation and analysis) was activated and the sample eluted in the back ‰ush mode onto the 250.2 mm C18 analytical column (HPLC II: G1312A binary pump, G1322A degasser, G1316A column thermostat). The analytes were separated using a linear methanol W 0.1z formic acid gradient running from 65z to 95z methanol in 9 min. Signals were recorded using an electrospray single stage quadrupole mass spectrometer (G1946A mass selective detector). The mass spectrometer was run in the single ion mode and focused on the [M＋Na] ＋ of cyclosporine and ascomycin (internal standard). Since under the conditions used, the sodium adducts [M＋Na] ＋ give the strongest signals, the mass spectrometer was focused on m W z＝815 (ascomycin), the internal standard, and m W z ＝1226 (cyclosporine), with a dwell time of 129 ms. Method validation is described in detail by Christians et al.
3)
Pharmacokinetic analysis: The pharmacokinetic parameters Cmax, Tmax, AUC0-last, AUC0-/, CL W F, and t1 W 2 were determined after oral administration and Cmax, AUC0-last, AUC0-/, CL, and t1 W 2 after intravenous infusion based on non-compartmental methods using WinNonlin Professional software (version 2.1, Pharsight Inc., Mountain View, CA). The values for Cmax and the time to reach Cmax (Tmax) were obtained directly from the concentration-time proˆle of the data. Individual concentration-time proˆles were plotted, and the elimination rate constant was determined by the logarithmic regression of the time points in the terminal elimination phase. Since the terminal phase should be the same for both intravenous and oral cyclosporine, the terminal phase in each subject was calculated using both the intravenous and oral data to determine a unied terminal t1 W 2 value. AUC0-last signiˆes the area under the concentration-time curve from time 0 to the last quantiˆable drug concentration. AUC0-/ for oral cyclosporine was calculated taking into account the concentration of cyclosporine at time 0 on day 3, and adjusting for the continued elimination of cyclosporine remaining from day 2 using the formula: Adjusted Day 3 AUC0-/(＝[(Day 3 AUC0-/)-((Day 3 C0) ・(t 1 W 2 W ln 2))]. Absolute oral bioavailability was calculated based on the AUC0-/, after oral and intravenous cyclosporine administration. The AUC0-last and AUC0-/ were compared after logarithmic transformation.
Statistical analysis: All data are reported as the mean±standard deviation. Statistical tests used were the Pearson product correlation, one-way ANOVA and, where indicated, the Student's paired t-test (a＝0.05, b ＝0.8). All statistical analyses were done using Sigmastat (Jandel Scientiˆc, San Rafael, CA).
Results

Protease inhibitors:
The pharmacokinetic parameters for the 7 subjects on nelˆnavir are reported in Table 2 . There was no signiˆcant diŠerence in the initial concentration (C 0 ) of NFV on Days 1, 2, or 3 (p＝ 0.34). When intravenous cyclosporine was administered concomitantly with nelˆnavir, no signiˆcant change in nelˆnavir pharmacokinetics was observed (see Fig. 1 ).
When oral cyclosporine was added to nelˆnavir, however, there was a signiˆcant increase in T max from 2.6±0.9 to 3.2±0.8 h (p＝0.01), and 6 of 7 subjects exhibited an increase in AUC0-/, with the mean values increasing from 27.9±15.2 to 43.2±27.1 mg・hr W mL (Fig. 1) . This diŠerence approached, but did not achieve, signiˆcance (p＝0.06) given the variability in the data and the small sample size.
Cyclosporine: Individual subject pharmacokinetic parameters for intravenous and oral CsA are given in Table 3 . The mean values for the 7 subjects receiving nelˆnavir were nearly identical to the mean values for all nine subjects, including those taking IND (data not shown). CsA bioavailability ranged from 15-58z. The range for oral CsA AUC0-/ was fairly wide in this study (3.2¿13.9 mg・hr W mL). The mean AUC0-/ for oral CsA was signiˆcantly lower than with intravenous CsA (8.5±3.1 vs. 11.9±4.0 mg・hr W mL, pÃ0.05).
Clearance of intravenous CsA given with PIs was 0.18 ±0.04 L W h W kg (n＝9). CL W F for the oral CsA (Neoral } ) dose with PIs was 0.58±0.29 L W hr W kg. Reanalyzing the data for CsA to include only those subjects only on NFV, the intravenous and oral clearance changed minimally (CL 0.19±0.03 L W h W kg; CL W F 0.62±0.32 L W h W kg; n＝7).
Discussion
Drug absorption is aŠected by the presence of Pglycoprotein and CYP3A4 in the intestinal epithelial cells. 1) Concomitant administration of drugs that inter- act with the P-glycoprotein-CYP3A4 system, such as CsA and PIs which are substrates and inhibitors of both systems, has been shown to cause greater drug-drug interactions than when the drugs are given several hours apart. 4) Had we given the drugs a few hours apart, we should have seen less interaction. In the current study, and in the solid organ transplantation study being done in HIV＋ patients at UCSF, the medications are taken at the same time. 5) In the current study, cyclosporine interacted with protease inhibitors when both are given orally, resulting in marginal increases in NFV AUC0-last and signiˆcant increases in NFV Tmax ( Table 2) . Similar trends were seen with indinavir, even with the limited sample size (data not shown). In contrast, intravenous administration of CsA had little eŠect on oral NFV pharmacokinetics. The mean AUC0-/ for oral CsA was similar to the approximated AUC0-/ for normal Caucasians given a similar oral dose of CsA (7.2±1.5 mg・hr W mL for 4 mg).
6) The intersubject variability in CsA AUC when given orally was 37z, approximately twice the intersubject variability seen in renal transplant subjects on Neoral } . 7a) This was re‰ected also in the range of bioavailability of CsA among our subjects, from 15z (subject 5) to 58z (subject 9). From Min et al., 6) intersubject bioavailability for Neoral } varied approximately 18z in healthy Caucasians, while in our study the bioavailability varied 43z.
Clearance of intravenous CsA given with protease inhibitors (0.18±0.04 L W h W kg; n＝9) was similar to that reported by Min et al. 6) for intravenous CsA given alone (0.22±0.03 L W hr W kg), and ¿30z less than that reported by Novartis. 7a) CL W F for the oral CsA (Neoral } ) dose with protease inhibitors was higher than that reported by the literature for cyclosporine (Neoral } ) in renal transplant patients (0.58±0.29 vs. 0.47±0.17 L W hr W kg), 7a) whose renal function is normal post-transplant. However, the CL W F for the oral CsA (Neoral } ) dose with protease inhibitors was similar to that reported in healthy Caucasians (0.58±0.29 vs. 0.58±0.09 L W hr W kg). 6) For those subjects on nelˆnavir, the intravenous and oral CsA clearance changed minimally (CL 0.19± 0.03 L W h W kg; CL W F 0.62±0.32 L W h W kg; n＝7).
Results from the current study show a wide degree of variability in the PK parameters of NFV as well as CsA. In the subjects studied, there was marked intersubject variability and the changes in the PK parameters were inconsistent between individuals in terms of direction and extent. Preliminary data from our current study of solid organ transplantation reveal that the average pretransplant NFV AUC was 17.5＋ W -6.5 mg*h W L (n＝4) (personal communication), while the reported value in the literature for NFV AUC(0-12) was 27.0＋ W -7.4 mg * h W L. 8) NFV and CsA, both function as substrates and inhibitors of P-gp mediated drug eOEux (Ki＝ 1.09 and 28.6 mM, respectively 9) ), and concomitant oral administration would be expected to increase the bioavailability of both compounds. In the current study, the oral administration of both CsA and NFV did not appreciably enhance CsA exposure, but increased the NFV AUC to a degree that was nearly signiˆcant (Tables 2 and 3).
6)
Additionally, some subjects were taking other medications, which also interacted with P-glycoprotein or CYP3A4. For instance, three subjects were on more than one protease inhibitor (see Table 1 ) with two subjects taking saquinavir. Saquinavir (SQN) is a much less potent P-glycoprotein and CYP3A4 inhibitor, and should not increase concomitant nelˆnavir levels more than 6z, however. 7b) Many other medications taken by HIV＋ patients, such as antifungals, antihyperlipidemics (HMG-CoA reductase inhibitors or``statins''), herbs, and proton-pump inhibitors, can also inhibit Pglycoprotein and CYP3A4. 10) For example, Subject 7 was on the HMG-CoA reductase inhibitor pravastatin, which has the potential to increase hepatic transporter levels (MDR1), may aŠect the levels of drugs that are substrates, 11) and is a potential contributing source of the observed PK variability. Subject 5 was taking nevirapine, which is a weak CYP3A4 inducer, concomitantly with SQN and nelˆnavir. Nevirapine decreases SQN AUC by 24z and Cmax by 28z 7e) and has been shown in one study to reduce NFV exposure by nearly 50z.
12) The clinical signiˆcance of nevirapine's eŠects on NFV and SQN pharmacokinetics, however, is unclear. Of note, this pilot study was conducted in HIV ＋ patients with su‹cient manifestations of their disease that they had also been started on antiretroviral therapy; recruitment of a more homogenous patient population on antiretrovirals, but taking few other medications, would have been considerably more di‹cult.
Another potential source of variability among the subjects is the polymorphic expression in P-glycoprotein. P-glycoprotein polymorphisms may either increase or decrease the function of P-glycoprotein, thereby respectively decreasing or increasing the exposure of drugs that are P-glycoprotein substrates. 13) These P-glycoprotein polymorphisms may be the reason for diŠerences in cyclosporine and tacrolimus pharmacokinetic parameters seen among healthy Caucasian and African-American volunteers. 6, 14) Since genotyping was not conducted in our study, the role of Pglycoprotein polymorphisms in the variable pharmacokinetics of protease inhibitors or cyclosporine in these patients is unknown.
A potential critique of our study was the crossover design utilized. Pharmacokinetic studies with intravenous CsA demonstrate some variability in pharmacokinetic parameters, although not as much as with oral CsA. 15) In our HIV subjects, CsA half-life was long enough to produce detectable mean CsA levels 24 hours after dosing (Day 3 C0＝226±141), although this is mostly due to high Day 3 C0 levels from the three subjects (＃2, 5, 8) taking multiple protease inhibitors. To take this into account, the AUC corresponding to the elimination of CsA remaining from t＝0 on Day 3 was calculated (see Methods) and subtracted from the measured CsA AUC for Day 3.
The purpose of this observational pilot study was to obtain an estimate of the degree of interaction between cyclosporine and protease inhibitors before starting the larger solid organ transplant study now underway at UCSF, and was not speciˆcally designed to allow us to predict the amount of variability between cyclosporine and protease inhibitors. In fact, our results demonstrate that the heterogeneity of the population and the highly variable pharmacokinetics made predictions di‹cult.
In clinical practice, our HIV＋ transplant patients receive CsA and protease inhibitors together, the doses of these medications are adjusted as needed, and other medicines that inhibit or induce CYP3A4 and P-gp are added or removed from the patient's therapeutic regimen. The combination of the variability of individual pharmacokinetic studies, narrow therapeutic windows for the medications, and a tendency towards increased cyclosporine bioavailability in the presence of protease inhibitors make a compelling case in these vulnerable patients for routine therapeutic drug monitoring for both cyclosporine and protease inhibitors. 
